Alex Wyatt
@ResearchWyatt
Followers
2K
Following
3K
Media
192
Statuses
1K
Prostate cancer genomics and ctDNA. Associate Prof for a precision oncology team @VanProstateCtr @UBCmedicine @BCCancer_GSC
Vancouver, British Columbia
Joined August 2017
Here’s our @Nature paper on v deep whole-genome sequencing of serial ctDNA and met tissue. @cherberts1, Matti, Joonatan et al applied new methods to give fascinating insight into temporal #ProstateCancer clonal complexity and evolution of resistance. 1/7 https://t.co/xTqXwj83JP
44
177
636
Understanding ctDNA technology applications for cancer detection and characterization. @ResearchWyatt @VanProstateCtr joins @UroDocAsh @MDAndersonNews to break down the fundamentals of cell-free DNA and how ctDNA represents the tumor-derived portion of these fragments in the
1
5
15
Really honoured to get to collaborate on this @CDNCancerTrials PC-BETS study. and to present substudy G at #ASCO25 - carboplatin for mCRPC with DDR alterations detected in ctDNA (@ResearchWyatt)
0
4
20
Clonal hematopoiesis (CH) in the @ANZUPtrials #TheraP study @ASCO #ASCO25 presented by Asli Munzur ■ ¹⁷⁷Lu-PSMA-617: higher incidence of emergent CH compared to cabazitaxel chemotherapy ■ Most new clonal hematopoiesis mutations ¹⁷⁷Lu-PSMA-617 fall in DNA damage repair
1
16
46
Stunning research from @EdmondMKwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative
2
45
139
So many to thank that played an outsized role in making this possible. Special mention to close friends in @ResearchWyatt lab for keeping me level-headed for last 2-3 years, @VanProstateCtr for providing a home away from home, @ANZUPtrials for bridging my return home through
2
3
13
On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the @ANZUPtrials phase II TheraP study, now published in @NatureMedicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across
13
42
104
Hot of the press in @JournalofNucMed ... with 10 years experience in Lutetium-177 PSMA radioligand therapy we describe a 1.3% incidence of myelodysplasia. We deep dive on each case with remarkable findings. One patient who participated in the @ANZUPtrials #TheraP trial had
0
40
92
Elegant presentation from @ResearchWyatt on the evolution of ctDNA detection and characterization! Session chaired by @DanaFarber_GU's @OncoBellmunt and @BartsECMC 's @b_szabados
#GU25 @ASCO @OncoAlert @OncLive
1
17
47
🔥 ctDNA Testing: Smoke Detector vs. Fire Investigation! 🔥 Nice analogy by @ResearchWyatt 🧬🧬🧬Not all ctDNA tests serve the same purpose! Some detect cancer early (like a smoke detector), while others characterizetumor properties to guide treatment (like a fire
0
8
28
Thank you to funders, especially to @tfri_research for supporting this prostate cancer research in my team! We're applying cfChIP-seq to more patient samples in 2025 including a big expansion to advanced bladder cancer via generous grant support from @BladderCancerUS
0
1
4
I'm not sure cfChIP-seq is *immediately* clinic-ready partly because low ctDNA% samples are much less informative, but I’m excited to see where M Freedman, @jberchuck, @SylvanBacaLab, and other pioneers will take this emerging technology in prostate cancer!
1
0
4
At the moment, I think of this technique (plasma cfChIP-seq) as a tool to help us learn about metastatic biology, treatment resistance and therapeutic vulnerabilities - in 1000s of patients and in a way that wasn’t previously possible in a bone-predominant cancer.
1
0
2
What we can learn from histone modifications on prostate cancer ctDNA? Here’s our collaboration with David Takeda (NIH) where we performed cfChIP-seq for H3K4me2 on ctDNA from an aggressive set of mCRPC. Insights into patient-to-patient disease biology! https://t.co/vYTxSZIuR8
1
8
36
Here's our latest, led by Drs. Riaz Gillani & @RyanLCollins13 - we studied a type of inherited genetic event (structural variants) + risk of developing certain cancers in kids: @DanaFarberNews @DFCIPopSci @BostonChildrens @broadinstitute @ScienceMagazine
science.org
Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using...
8
48
168
Our paper out today in @NatureComms analyzed plasma from the phase 3 @ALLIANCE_org A031201 trial using the AR-ctDETECT assay. Patients positive for circulating tumor DNA had poor overall survival despite treatment with potent AR inhibitors.
6
14
60
The last time Felix stood on our stage, after a beautiful talk by @mishabeltran & intro by @AminaZoubeidi 💔💔💔 https://t.co/HUinL3Jc4X
Felix was the best of us. I'm heartbroken by his passing.💔His spirit of generosity, kindness, humility, his humor, intelligence & scientific acumen - you made us better scientists & better people, Felix. Love & miss you always. My deepest condolences to @MaryFengMD & family.🙏♥️
0
12
47
How does AR activation affect gene expression? Our new paper shows it’s less about creating new loops and more about amplifying contact frequency in existing ones. Explore in @NatureComms ( https://t.co/LozFmiNyni) Tweetorial below: #AR #Epigenetics #prostatecancer
3
7
19